CHMMF (Chimeric Therapeutics) Interest Received: $0.02 Mil (TTM As of Dec. 2025)


CHMMF Chimeric Therapeutics Ltd CHMMF
13 GF Score
Price $0.10
! 1 Warning Sign
View Full Analysis

What is Chimeric Therapeutics Interest Received?

Chimeric Therapeutics CHMMF -96.67% 13 Interest Received is $0.02 Mil as of Dec. 2025. GuruFocus rates CHMMF with a GF Score™ of 13/100. The stock has 1 warning sign investors should review.

Chimeric Therapeutics's Interest Received for the six months ended in Dec. 2025 was $0.02 Mil.

Chimeric Therapeutics's Interest Received for the trailing twelve months (TTM) ended in Dec. 2025 was $0.02 Mil.

Chimeric Therapeutics Interest Received Related Terms

Chimeric Therapeutics Interest Received Historical Data

* Premium members only.

The historical data trend for Chimeric Therapeutics's Interest Received can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chimeric Therapeutics Interest Received Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Interest Received
0.00 0.00 0.02 0.08 0.03

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Received Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.02
CHMMF
13GF Score
Chimeric Therapeutics Ltd CHMMF
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chimeric Therapeutics Interest Received Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Interest Received represents interest received by the company in the direct cash flow method.

Interest Received for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Received →
What does a Interest Received of $0.02 Mil mean?
Chimeric Therapeutics (CHMMF) has a Interest Received of $0.02 Mil as of Dec. 2025. Interest Received represents interest received by the company in direct cash flow method. View historical data for Chimeric Therapeutics and its competitors.
Is Chimeric Therapeutics' Interest Received too high?
Chimeric Therapeutics' current Interest Received is $0.02 Mil. Overall, Chimeric Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Chimeric Therapeutics' Interest Received compare to VRTX and REGN?
Chimeric Therapeutics' Interest Received of $0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Received for a Biotechnology company?
A good Interest Received depends on the Biotechnology industry context. However, Interest Received should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Received mean?
A high Interest Received can signal that a stock is expensive relative to its fundamentals. Interest Received represents interest received by the company in direct cash flow method. View historical data for Chimeric Therapeutics and its competitors. Chimeric Therapeutics's current Interest Received is $0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chimeric Therapeutics stock overvalued right now?
Chimeric Therapeutics (CHMMF) has a current Interest Received of $0.02 Mil. The current Interest Received is $0.02 Mil. Chimeric Therapeutics' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Received calculated?
Interest Received is calculated from a company's financial statements. For Chimeric Therapeutics (CHMMF), the current Interest Received is $0.02 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chimeric Therapeutics Business Description

Other Exchanges CHM:Australia
Address 62 Lygon Street, Level 3, Carlton, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.
13GF Score

Get the complete analysis for CHMMF

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.10
Price